Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BioDrugs
Published in: BioDrugs 5/2013

01-10-2013 | Adis Drug Evaluation

Lixisenatide: A Review of Its Use in Patients with Type 2 Diabetes Mellitus

Author: Lesley J. Scott

Published in: BioDrugs | Issue 5/2013

Login to get access

Abstract

Lixisenatide (Lyxumia®) is a glucagon-like peptide-1 receptor agonist that acts in a glucose-dependent manner to improve glycemic control in adult patients with type 2 diabetes mellitus. Subcutaneous once-daily prandial lixisenatide is indicated for the treatment of adult patients with type 2 diabetes to achieve glycemic control in combination with oral antihyperglycemic drugs (OADs) and/or basal insulin when these antihyperglycemic drugs do not provide adequate glycemic control. In an extensive phase III clinical trial program, lixisenatide once daily in combination with OADs and/or basal insulin for 24 weeks improved glycemic control, had beneficial effects on bodyweight, and was generally well tolerated in adult patients with inadequately controlled type 2 diabetes despite treatment with OADs and/or basal insulin. At 24 weeks, in terms of the primary efficacy endpoint of each trial, combination therapy with lixisenatide was associated with better efficacy than placebo in patients inadequately controlled on OADs and/or basal insulin, was shown to be noninferior to exenatide in patients inadequately controlled on background metformin therapy, and showed similar efficacy to sitagliptin in patients inadequately controlled on background metformin therapy. Further clinical experience/post-marketing surveillance studies and long-term safety data, along with pharmacoeconomic analyses, are required to fully define the position of lixisenatide in relation to other antihyperglycemics. In the meantime, once-daily prandial lixisenatide in combination with OADs and/or basal insulin (plus diet and exercise) is an effective option for improving glycemic control in adult patients with type 2 diabetes, including in patients where bodyweight loss is an essential component in their management.
Literature
1.
2.
Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes. Diabetes Care. 2012;35:1364–79.PubMedCrossRef
3.
Sherwin R, Jastreboff AM. Year in diabetes 2012: the diabetes tsunami. J Clin Endocrinol Metab. 2012;97(12):4293–301.PubMedCrossRef
4.
Nauck MA. Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications. Am J Med. 2011;124 Suppl.:S3–18.
5.
Nauck MA. Unraveling the science of incretin biology. Am J Med. 2009;122 Suppl.:S3–10.
6.
Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696–705.PubMedCrossRef
7.
Malm-Erjefalt M, Bjornsdottir I, Vanggaard J, et al. Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase. Drug Metab Dispos. 2010;38(11):1944–53.PubMedCrossRef
8.
Fonseca VA, Alvarado-Ruiz R, Raccah D, et al. Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono). Diabetes Care. 2012;35(6):1225–31.PubMedCrossRef
9.
Thorkildsen C, Neve S, Larsen BD, et al. Glucagon-like peptide 1 receptor agonist ZP10A increases insulin mRNA expression and prevents diabetic progression in db/db mice. J Pharmacol Exp Ther. 2003;302(2):490–6.CrossRef
10.
Werner U, Haschke G, Herling AW, et al. Pharmacological profile of lixisenatide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes. Regul Pept. 2010;164(2–3):58–64.PubMedCrossRef
11.
Horowitz M, Rayner CK, Jones KL. Mechanisms and clinical efficacy of lixisenatide for the management of type 2 diabetes. Adv Ther. 2013;30(2):81–101.PubMedCrossRef
12.
Werner U, Gerlach M, Hofmann M, et al. Combination of lixisenatide and insulin glargine demonstrates complementary pharmacological activity on glycemic control in animal models of diabetes [abstract no.1051-p]. Diabetes. 2012;61 Suppl.1:A270.
13.
14.
Kapitza C, Forst T, Coester H-V, et al. Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes inadequately controlled on metformin. Diabetes Obes Metabol. 2013;15(7):642–9.CrossRef
15.
Becker RH, Kapitza C, Stechl J, et al. Restitution of glucose disposition with lixisenatide in subjects with type 2 diabetes [abstract no.813]. Diabetologia. 2012;55 Suppl.1:S335–S6.
16.
Becker RHA, Ruus P, Li YH, et al. Restoration of insulin release with lixisenatide in patients with type 2 diabetes [abstract no. 850]. Diabetologia. 2010;53 Suppl.1:S339.
17.
Stechl J, Becker RH, Kapitza C, et al. Augmentation of first-phase insulin release with lixisenatide in nondiabetic subjects [abstract no. 814]. Diabetologia. 2012;55:S336.
18.
Ratner RE, Hanefeld M, Shamanna P, et al. Post-meal pharmacodynamic profile of lixisenatide once daily vs placebo in T2DM insufficiently controlled on SU ± metformin (GetGoal-S) [abstract no. D-0743]. 21st World Congress of the International Diabetes Federation, Dubai; 4–8 Dec 2011.
19.
Lorenz M, Pfeiffer C, Steinstraser A, et al. Effects of lixisenatide once daily on gastric emptying in type 2 diabetes: relationship to postprandial glycemia. Regul Peptides. 2013;185C:1–8.CrossRef
20.
Hubschle T, Schafer HL, Juretschke HP, et al. Anti-atherosclerotic activity of lixisenatide in ApoE knockout mice [abstract no. 809]. Diabetologia. 2012;55 Suppl.1:S334.
21.
Wohlfart P, Linz W, Hubschle T, et al. Cardioprotective effects of lixisenatide in rat myocardial ischaemia-reperfusion injury studies. J Transl Med. 2013;11:84.PubMedCrossRef
22.
Liu Y-H, Ruus P. Effect of GLP-1 receptor agonist AVE0010 on the absorption of concomitant oral drugs: acetaminophen and ethinylestradiol/levonorgestrel [abstract no. 776]. 45th Annual Meeting of the European Association for the Study of Diabetes, Vienna; 29 Sep–2 Oct 2009.
23.
Liu YH, Ruus P, Steinstraesser A, et al. Effect of the GLP-1 agonist lixisenatide on the pharmacokinetics of warfarin [abstract no. 2128-PO]. 70th Annual Scientific Sessions of the American Diabetes Association, Orlando; 25–29 Jun 2010.
24.
Dahmen R, Steinstraesser A, Poitiers F, et al. Interaction of subcutaneous lixisenatide 20 μg QD on pharmacokinetic and pharmacodynamic properties of oral ramipril 5 mg QD [abstract]. Basic Clin Pharmacol Toxicol. 2011;109 Suppl.:89.
25.
Bolli G, Munteanu M, Dotsenko S, et al. Efficacy and safety of lixisenatide once-daily versus placebo in patients with type 2 diabetes mellitus insufficiently controlled on metformin (GetGoal-F1) [abstract no. 784]. Diabetologia. 2011;54(Suppl. 1):S316–7.
26.
Ahren B, Leguizamo A, Miossec P, et al. Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M). Diabetes Care. 2013. doi:10.​2337/​dc12-2006.PubMed
27.
Pan CY, Zhao Q, Niemoeller E. Lixisenatide in Asian patients with type 2 diabetes (T2DM) uncontrolled on metformin ± sulfonylurea (SU): GetGoal-M Asia [abstract no. PCS-20-3]. J Diabetes Invest. 2012;3 Suppl.1:204.
28.
Ratner RE, Hanefeld M, Shamanna P, et al. Efficacy and safety of lixisenatide once-daily versus placebo in patients with type 2 diabetes mellitus insufficiently controlled on sulfonylurea ± metformin (GetGoal-S) [abstract no. 785]. Diabetologia. 2011;54 Suppl.1:S317.
29.
Pinget M, Goldenberg R, Niemoeller E, et al. Efficacy and safety of lixisenatide once daily versus placebo in patients with type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P). Diabetes Obes Metab. 2013. doi:10.​1111/​dom.​12121.
30.
Riddle MC, Aronson R, Home P, et al. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L). Diabetes Care. 2013. doi:10.​2337/​dc12-2454.
31.
Seino Y, Min KW, Niemoeller E, et al. Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia). Diabetes Obes Metab. 2012;14(10):910–7.PubMedCrossRef
32.
Riddle MC, Forst T, Aronson R, et al. Adding once-daily lixisenatide in type 2 diabetes inadequately controlled with newly initiated insulin and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-DUO-l). Diabetes Care. 2013. doi:10.​2337/​dc12-2462.
33.
Rosenstock J, Raccah D, Koranyi L, et al. Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: a 24-week, randomized, open-label, active-controlled study (GetGoal-X). Diabetes Care. 2013. doi:10.​2337/​dc12-2709.
34.
35.
Sanofi. 24-week study comparing lixisenatide (AVE0010) to sitagliptin as add-on to metformin in obese type 2 diabetic patients younger than 50 [ClinicalTrials.gov identifier NCT00976937]. US National Institutes of Health, ClinicalTrials.gov; 2012. http://​www.​clinicaltrials.​gov (Accessed 9 April 2013).
36.
Sanofi. GLP-1 agonist AVE0010 in patients with type 2 diabetes for gylcemic control and safety evaluation, on top of sulfonylurea (GetGoal-S) [ClinicalTrials.gov identifier NCT00713830]. US National Institutes of Health, ClinicalTrials.gov; 2012. http://​www.​clinicaltrials.​gov (Accessed 12 Apr 2013).
37.
Sanofi. Efficacy and safety of lixisenatide in patients with type 2 diabetes mellitus insufficiently controlled by metformin (GetGoal-M-Asia) [ClinicalTrials.gov identifier NCT01169779]. US National Institutes of Health, ClinicalTrials.gov; 2012. http://​www.​clinicaltrials.​gov (Accessed 12 Apr 2013).
38.
Sanofi. GLP-1 agonist AVE0010 in patients with type 2 diabetes for gylcemic control and safety evaluation, on top of metformin (GetGoal-F1) [ClinicalTrials.gov identifier NCT00763451]. US National Institutes of Health, ClinicalTrials.gov; 2012. http://​www.​clinicaltrials.​gov (Accessed 12 Apr 2013).
39.
Ratner RE, Rosenstock J, Boka G, et al. Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial. Diabet Med. 2010;27(9):1024–32.PubMedCrossRef
40.
Raccah D, Miossec P, Esposito V, et al. Efficacy and safety of lixisenatide in elderly (≥65 years) and very elderly (≥75 years) patients with type 2 diabetes: an analysis from the GetGoal Phase 3 programme [abstract no. 815]. Diabetologia. 2012;55 Suppl.1:S336.
41.
Bolli G, Munteanu M, Dotsenko S, et al. Long-term (up to 2 years) safety of lixisenatide once daily vs placebo in T2DM insufficiently controlled on metformin (GetGoal-F1) [abstract no. O-0595]. 21st World Congress of the International Diabetes Federation, Dubai; 4–8 Dec 2011.
42.
43.
44.
Zhang Y, Hu G, Yuan Z, et al. Glycosylated hemoglobin in relationship to cardiovascular outcomes and death in patients with type 2 diabetes: a systematic review and meta-analysis. PLoS ONE. 2012;7(8):e42551.PubMedCrossRef
45.
Node K, Inoue T. Postprandial hyperglycaemia as an etiological factor in vascular failure. Cardiovasc Diabetol. 2009;8:23.PubMedCrossRef
46.
Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycaemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care. 2003;26(3):881–5.PubMedCrossRef
47.
Bonora E, Muggeo M. Postprandial blood glucose as a risk factor for cardiovascular disease in type II diabetes: the epidemiological evidence. Diabetologia. 2001;44(12):2107–14.PubMedCrossRef
48.
UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatments and risk of complications in patients with type 2 diabetes. Lancet. 1998;352:837–53.CrossRef
49.
Turnbull FM, Abraira C, Anderson RJ, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia. 2009;52(11):2288–98.PubMedCrossRef
50.
Ray KK, Seshasai SR, Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet. 2009;373(9677):1765–72.PubMedCrossRef
51.
Kelly TN, Bazzano LA, Fonseca VA, et al. Systematic review: glucose control and cardiovascular disease in type 2 diabetes. Ann Intern Med. 2009;151(6):394–403.PubMedCrossRef
52.
Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577–89.PubMedCrossRef
53.
Selvin E, Marinopoulos S, Berkenblit G, et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med. 2004;141(6):421–31.PubMedCrossRef
54.
Stolar M. Glycemic control and complications in type 2 diabetes mellitus. Am J Med. 2010;123:S3–11.PubMedCrossRef
55.
Del Prato S, LaSalle J, Matthaei S, et al. Tailoring treatment to the individual in type 2 diabetes practical guidance from the Global Partnership for Effective Diabetes Management. Int J Clin Pract. 2010;64(3):295–304.PubMedCrossRef
56.
Monnier L, Colette C, Dunseath GJ, et al. The loss of prandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes. Diabetes Care. 2007;30(2):263–9.PubMedCrossRef
57.
Riddle M, Umpierrez G, DiGenio A, et al. Contributions of basal and postprandial hyperglycemia over a wide range of A1C levels before and after treatment intensification in type 2 diabetes. Diabetes Care. 2011;34(12):2508–14.PubMedCrossRef
58.
59.
Bailey CJ, Kodack M. Patient adherence to medication requirements for therapy of type 2 diabetes. Int J Clin Pract. 2011;65(3):314–22.PubMedCrossRef
60.
61.
62.
Tahrani AA, Bailey CJ, Del Prato S, et al. Management of type 2 diabetes: new and future developments in the treatment. Lancet. 2011;378:182–97.PubMedCrossRef
63.
Ghosh RK, Ghosh SM, Chawla S, et al. SGLT2 inhibitors: a new emerging class in the treatment of type 2 diabetes mellitus. J Clin Pharmacol. 2012;52:457–63.PubMedCrossRef
64.
DeFronzo RA, Davidson JA, Del Prato S. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes Metabol. 2012;14:5–14.CrossRef
65.
Hirshberg B, Raz I. Impact of the US Food and Drug Administration cardiovascular assessment requirements on the drug development of novel antidiabetes drugs. Diabetes Care. 2011;34 Suppl.2:S101–6.
66.
Sanofi. Evaluation of cardiovascular outcomes in patients with type 2 diabetes after acute coronary syndrome during treatment with AVE0010 (lixisenatide) (ELIXA) [ClinicalTrials.gov identifier NCT01147250]. US National Institutes of Health, ClinicalTrials.gov; 2013. http://​www.​clinicaltrials.​gov (Accessed 9 May 2013).
67.
Singh S, Chang H-Y, Richards TM, et al. Glucagon like peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus. JAMA Intern Med. 2013;173(7):534–9.PubMedCrossRef
68.
Butler AE, Campbell-Thompson M, Gurlo T, et al. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes. 2013;62:2595–604.PubMedCrossRef
69.
Elashoff M, Matveyenko AV, Gier B, et al. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology. 2011;141:150–6.PubMedCrossRef
70.
Nauck MA. A critical analysis of the clinical use of incretin-based therapies: the benefits by far outweigh the potential risks. Diabetes Care. 2013. doi:10.​2337/​dc12-2504.
71.
72.
Metadata
Title
Lixisenatide: A Review of Its Use in Patients with Type 2 Diabetes Mellitus
Author
Lesley J. Scott
Publication date
01-10-2013
Publisher
Springer International Publishing
Published in
BioDrugs / Issue 5/2013
Print ISSN: 1173-8804
Electronic ISSN: 1179-190X
DOI
https://doi.org/10.1007/s40259-013-0057-y

Other articles of this Issue 5/2013

BioDrugs 5/2013 Go to the issue

Current Opinion

Genome-Based Bacterial Vaccines: Current State and Future Outlook

Review Article

Evolving Approaches to Metastatic Breast Cancer Patients Pre-treated with Anthracycline and Taxane

Erratum

Erratum to: Evolving Approaches to Metastatic Breast Cancer Patients Pre-treated with Anthracycline and Taxane

Leading Article

The Th17 Pathway as a Therapeutic Target in Rheumatoid Arthritis and Other Autoimmune and Inflammatory Disorders

Adis Drug Clinical Q&A

Pegylated Liposomal Doxorubicin: A Guide to Its Use in Various Malignancies

Current Opinion

The Arrival of JAK Inhibitors: Advancing the Treatment of Immune and Hematologic Disorders